[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"kras-mutation-related-tumors\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:kras-mutation-related-tumors":44},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,92,114,139],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":59,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":91},"100499720","phase-1-phase-12-trial-of-s241656-in-selected-rasmapk-mutation--positive-malignancies-100499720",false,"NCT05786924","Phase 1\u002F2 Trial of S241656 in Selected RAS\u002FMAPK Mutation- Positive Malignancies","A Phase 1\u002F2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With KRAS, BRAF and Other Selected RAS\u002FMAPK Mutation-Positive Malignancies","Key Inclusion Criteria:\n\n* Life expectancy of ≥ 12 weeks in the opinion of the investigator.\n* Histologically or cytologically confirmed recurrent locally advanced (unresectable) or metastatic solid tumors with documented RAS or RAF mutations or alterations.\n* Adequate bone marrow and organ function.\n* Recovered from toxicity to prior anti-cancer therapy.\n\nPart 1 Dose Escalation cohort ONLY:\n\n* Part 1A: Advanced\u002Fmetastatic NSCLC with KRAS non-G12C, HRAS, NRAS, BRAF or CRAF (RAF1) mutations or alterations\n* Part 1B: Advanced\u002Fmetastatic GI tumors (e.g., PDAC, CRC, and BTC) with KRAS, HRAS, NRAS, BRAF, and\u002For CRAF (RAF1) mutations or alterations\n* Part 1C: Advanced\u002Fmetastatic PDAC with KRAS, HRAS, NRAS, BRAF, and\u002For CRAF (RAF1) mutations or alterations\n* Part 1D: Colorectal adenocarcinoma with KRAS, HRAS, NRAS, BRAF, and\u002For CRAF (RAF1) mutations or alterations\n* Part 1E: Other advanced\u002Fmetastatic non-GI, non-NSCLC solid tumors with KRAS, HRAS, NRAS, BRAF, CRAF (RAF1) mutations or alterations\n\nPart 2 Dose Optimization and Expansion cohorts ONLY:\n\n* Part 2A: Advanced\u002Fmetastatic NSCLC with KRAS non-G12C mutations and\u002For BRAF mutations\n* Part 2A1: Advanced\u002Fmetastatic NSCLC with KRAS non-G12C mutations\n* Part 2A2: Advanced\u002Fmetastatic NSCLC with BRAF mutations\n* Part 2A3: Advanced\u002Fmetastatic NSCLC with KRAS non-G12C or BRAF mutations or alterations and active CNS metastatic disease\n* Part 2A4: Advanced\u002Fmetastatic NSCLC with a KRAS G12C mutation\n* Part 2B1: Advanced\u002Fmetastatic PDAC with KRAS, HRAS, NRAS, BRAF, and\u002For CRAF (RAF1) mutations or alterations\n* Part 2B2: Advanced\u002Fmetastatic CRC with KRAS, HRAS, NRAS, BRAF, and\u002For CRAF (RAF1) mutations or alterations\n* Part 2B3: Advanced\u002Fmetastatic BTC (adenocarcinoma) with KRAS, HRAS, NRAS, BRAF, and\u002For CRAF (RAF1) mutations or alterations\n\nKey Exclusion Criteria:\n\n* Cancer that has a known MEK1\u002F2 mutation.\n* Known allergy\u002Fhypersensitivity to excipients of S241656 or to any of the registered IMPs administered in combination.\n* Any contra-indication, to use of any of the combination chemotherapy or anti-EGFR therapy partners administered as part of this trial.\n* Major surgery within 4 weeks of study entry or planned during study.\n* Ongoing anticancer therapy.\n* Ongoing radiation therapy.\n* Uncontrolled or active clinically relevant bacterial, fungal, or specific viral infection requiring systemic therapy.\n* Clinically significant cardiovascular disease.\n* Symptomatic spinal cord compression.\n* Evidence of active malignancy (other than study-specific malignancies) requiring systemic therapy within the next 2 years.\n* History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO.\n* Females who are pregnant or breastfeeding.\n* Actively receiving systemic treatment or direct medical intervention on another therapeutic clinical study.\n* Prior use of experimental agents that target the KRAS\u002FBRAF\u002FMEK\u002FERK pathway.","ALL","18 Years",{"count":19,"type":20},554,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","BDTX-4933-101 is a first-in-human, open-label, Phase 1\u002F2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies in participants with selected advanced malignancies. The study population for the Dose Escalation part of the study comprises adults with recurrent advanced\u002Fmetastatic non-small cell lung cancer (NSCLC), Gastrointestinal (GI) cancers, and other solid tumors harboring KRAS, HRAS, NRAS, BRAF, and\u002For CRAF (Rapidly Accelerated Fibrosarcoma (RAF1)) mutations or alterations. A dose optimization part in adults with NSCLC may follow the dose escalation phase if the sponsor, in consultation with the safety review committee, decides it is necessary to further characterize the optimal dose. However, the study may also proceed directly to the expansion phase. The study population for the Dose Expansion part of the study comprises adults with advanced\u002Fmetastatic NSCLC with KRAS and\u002For BRAF mutations, and with Pancreatic Ductal AdenoCarcinoma (PDAC), ColoRectal Cancer (CRC), and Biliary Tract Cancer (BTC) with KRAS, HRAS, NRAS, BRAF, and\u002For CRAF (RAF1) mutations and alterations. All patients will self-administer S241656 orally in 28-day cycles until disease progression, toxicity, withdrawal of consent, or termination of the study.",[27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58],"Non-small Cell Lung Cancer","Histiocytic Neoplasm","Histiocytosis","BRAF Gene Mutation","BRAF V600E","BRAF V600 Mutation","BRAF Mutation-Related Tumors","BRAF","Metastatic Lung Non-Small Cell Carcinoma","Metastatic Lung Cancer","Recurrent Lung Cancer","Recurrent Lung Non-Small Cell Carcinoma","NSCLC","Solid Tumor","Solid Carcinoma","KRAS G12D","KRAS G12V","KRAS Mutation-Related Tumors","NRAS Gene Mutation","Thyroid Cancer","Thyroid Carcinoma","Colorectal Cancer","Colorectal Carcinoma","Recurrent Histiocytic and Dendritic Cell Neoplasm","Brain Metastases","Recurrent NSCLC","KRAS G13C","Acquired Resistance to KRAS G12C Inhibitor","KRAS G12A","KRAS G12F","KRAS G12R","KRAS G13D",[60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78],"BRAF Class I","BRAF Class II","BRAF Class III","KRAS","Intolerant histiocytic neoplasm","BDTX-4933","Phase 1","dose escalation","dose expansion","MAPK","mitogen-activated protein kinase","RAS","RAF","Upstream oncogenic alterations","RAF inhibitor","intracranial disease","CRAF","NRAS","RAF fusions","RECRUITING","2026-06-16",{"date":82,"type":83},"2026-06-17","ACTUAL",{"date":85,"type":83},"2023-04-18",{"date":87,"type":20},"2028-06",{"name":89,"class":90},"Institut de Recherches Internationales Servier","OTHER",27,{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":99,"targetDuration":4,"studyType":21,"phases":101,"briefSummary":102,"conditions":103,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":113},"100490059","phase-1-nerofe-and-doxorubicin-in-kras-mutated-st2-positive-solid-tumors-100490059","NCT05661201","NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors","Phase I Study of NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors","Inclusion Criteria:\n\n* Advanced\u002Funresectable or metastatic solid tumor with a pathogenic KRAS mutation via polymerase chain reaction (PCR), next-generation sequencing (NGS), or other standard test (blood-based DNA testing is allowed)\n* Presence of tumor ST2 expression via immunochemistry assay\n* Progression or intolerance to all standard therapies, patient may decline standard therapies and retain eligibility (patients must not have available curative options); patients must have been exposed to 2 or fewer lines of systemic therapy for advanced disease (these patients would decline any unused standard therapies which are still available)\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2\n* Laboratory inclusion criteria:\n\n  * Absolute neutrophil count ≥ 1500\u002Fmm3\n  * Hemoglobin ≥ 9.0 g\u002FdL (transfusions are allowed to achieve this inclusion criterion)\n  * Platelets ≥ 100 x 109\u002FL (transfusions are NOT allowed to achieve this inclusion criterion)\n  * Creatinine clearance ≥ 50 mL\u002Fmin\u002F1.73 m2 using the formula: creatinine clearance = \\[\\[140 - age(yr)\\]\\*weight(kg)\\]\u002F\\[72\\*serum Cr(mg\u002FdL)\\] (multiply by 0.85 for women).\n  * AST and ALT ≤ 3 x the upper limit of normal of the institution's normal range and total bilirubin ≤ 1.5 x the upper limit of normal of the institution's normal range - if liver metastases are present, AST and ALT ≤ 5 x the upper limit of normal of the institution's normal range and total bilirubin ≤ 3 x the upper limit of normal of the institution's normal range unless there is persistent nausea, vomiting, right upper quadrant pain, fever, rash, or eosinophilia\n  * Partial Thromboplastin Time (PTT) must be ≤ 1.5 × upper limit of normal of institution's normal range and INR (International Normalized Ratio) \\\u003C 1.5. Subjects on anticoagulation (such as warfarin) will be permitted to enroll as long as the INR is in the acceptable therapeutic range as determined by the investigator\n* Patients must have fully recovered from all effects of surgery. Patients must have had at least two weeks after minor surgery and four weeks after major surgery before starting therapy. Minor procedures requiring \"twilight\" sedation such as endoscopies or mediport placement may only require a 24-hour waiting period, but this must be discussed with an investigator\n* Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to initiation of treatment and\u002For postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential\n* Patient is capable of understanding and complying with parameters as outlined in the protocol and able to sign and date the informed consent, approved by the Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures\n* Have measurable disease by RECIST v. 1.1\n* Have disease amenable to serial core tumor biopsies\n* Suitable, stable venous access to allow for all study-related blood sampling (a central line such as a portacath (e.g. Medi-Port) or PICC is highly encouraged)\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Prior exposure to anthracycline chemotherapy\n* Receiving any active anti-cancer therapy while on study treatment\n* Brain metastases unless they have been previously treated with surgery and\u002For radiation at least 4 weeks prior to C1D1 and have a baseline MRI that shows no evidence of active\u002Fprogressing intracranial disease\n* Anti-tumor therapy within 3 weeks of C1D1 (defined as, but not limited to, cytotoxic chemotherapy, immunotherapy, biological therapy, radiotherapy, and investigational agents), the \"wash-out period\"\n* Concurrent severe illness or uncontrolled medical condition that, in the investigator's judgement, would cause unacceptable safety risks\n* Women who are pregnant or breastfeeding\n* Concurrent use of an aromatase inhibitor\n* Psychiatric illness or social situation that would limit compliance with study requirements\n* Concurrent malignancy or malignancy within 2 years prior to starting study drug, with the exception of adequately treated, basal or squamous cell carcinoma, non-melanomatous skin cancer or curatively resected cervical cancer, or a malignancy that the investigator deems has been definitively treated (e.g. early stage prostate cancer)\n* Active hepatitis B, C, or HIV (patients with hepatitis C infection are eligible if they have an undetectable viral load following definitive treatment, patients with HIV are eligible if they have an undetectable viral load and a CD4 count above 500 cells\u002Fmm3)\n* Clinically significant, uncontrolled heart disease and\u002For cardiac repolarization abnormalities, including any of the following:\n\n  * History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty, or stenting) or symptomatic pericarditis within 6 months prior to screening\n  * History of documented congestive heart failure (New York Heart Association functional classification III-IV)\n  * Documented cardiomyopathy\n  * Left Ventricular Ejection Fraction (LVEF) \\\u003C50% as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO) at screening\n  * Clinically significant cardiac arrhythmias (e.g. ventricular tachycardia), complete left bundle branch block, high-grade AV block (e.g. bifascicular block, Mobitz type II and third-degree AV block)\n  * QTcF (using Fridericia's correction) of \\> 480 msec\n  * Long QT syndrome or family history of idiopathic sudden death or congenital long QT syndrome, or any of the following:\n\n    1. Risk factors for Torsades de Pointe (TdP) including uncorrected hypokalemia or hypomagnesemia, history of cardiac failure, or history of clinically significant\u002Fsymptomatic bradycardia.\n    2. Concomitant use of medication(s) with a known risk to prolong the QT interval and\u002For known to cause Torsades de Pointe that cannot be discontinued (within 5 half-lives or 7 days prior to starting study drug) or replaced by safe alternative medication\n    3. Inability to determine the QT interval on screening (QTcF, using Fridericia's correction)\n  * Systolic blood pressure (SBP) \\>160 mmHg or \\\u003C90 mmHg at screening",{"count":100,"type":20},24,[23],"The goal of this clinical trial is to learn about the safety of NEROFE and doxorubicin and how well it works in patients with advanced\u002Funresectable or metastatic solid KRAS-mutated and ST-positive solid tumors. The main question it aims to answer is to find the recommended dose and scheduled for the combination of NEROFE and doxorubicin. Participants will receive weekly doses of NEROFE and doxorubicin.",[40,44],"2026-03-04",{"date":106,"type":83},"2026-03-06",{"date":108,"type":83},"2023-04-12",{"date":110,"type":20},"2027-01",{"name":112,"class":90},"Georgetown University",1,{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":21,"phases":123,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":113},"100597863","phase-1-trial-of-single-protein-encapsulated-doxorubicin-spedox-6-in-advanced-malignancies-100597863","NCT07064018","Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies","Phase Ib\u002FIIa Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies","Inclusion Criteria:\n\n* Subjects ≥ 18 years at the first screening examination\u002Fvisit.\n* Subjects with advanced histologically or cytologically confirmed solid tumors (see below) refractory to or relapse from at least two previous therapies.\n* Tumor types expected to express lower levels of FcRn relative to normal tissue including: STS, TNBC, cervical cancer, NSCLC, ovarian cancer, and KRAS mutated pancreatic ductal adenocarcinoma without requirement for testing FcRn level.\n* Disease that is considered measurable by RECIST v1.1.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n* Life expectancy of at least 12 weeks.\n* Human Immunodeficiency Virus (HIV)-positive trial participants should be on established antiretroviral therapy (ART) for at least four weeks and have an HIV viral load less than 400 copies\u002FmL prior to enrollment.\n* Left ventricular ejection fraction \\> 50%.\n* Adequate organ function: (Hb ≥10 g\u002FdL, ANC ≥1,000\u002FµL3, and platelets\n\n  ≥100,000\u002FµL3), serum bilirubin ≤.5x the institutional upper limit of normal (ULN) (unless known Gilbert's disease), Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤3x ULN, and creatinine clearance \\>50 mL\u002Fmin as assessed by Cockcroft-Gault equation.\n* For patients with known Gilbert's disease, serum unconjugated bilirubin must be \\\u003C 4 mg\u002FdL.\n* Patient must have washed out of prior chemotherapy (at least 3 weeks from last end of therapy), radiotherapy (at least 4 weeks from last end of therapy), immunotherapy (at least 4 weeks from last end of therapy), other targeted therapies (at least 4 weeks from last end of therapy), or surgery (at least 4 weeks).\n* Recovery from toxicities of prior therapy. Toxicities should have recovered to CTCAE grade ≤ 1 or baseline with exception of alopecia.\n* Females of reproductive potential must have had a negative pregnancy test performed within 7 days prior to the start of treatment. Additionally, female subjects of reproductive potential should agree to use effective acceptable forms of contraception: surgical sterilization (tubal ligation); total abstinence from sexual intercourse with the opposite sex; established hormonal birth control (e.g., oral, transdermal, injection, or implant) plus a barrier method or a double barrier method (intrauterine device, spermicide, or a diaphragm plus condom) for at least 1 month prior to Cycle 1 Day 1 and agreement to use such a method during study participation and for an additional 6 months after the last dose of SPEDOX-6.\n* For males of reproductive potential: vasectomy or highly effective contraception (e.g., condoms, abstinence) during the study and for an additional 6 months after the last dose of SPEDOX-6.\n\nExclusion Criteria:\n\n* Patients with cancers with known driver mutations for which there are known and effective targeted therapies that have not received those therapies, but are able to. If a patient has received appropriate targeted treatment for their mutations and progressed, or those treatments are contraindicated, they will be considered potentially eligible.\n* Unstable angina pectoris, angioplasty, cardiac stenting, or myocardial infarction 6 months before study entry.\n* Untreated metastases to the Central Nervous System (CNS).\n* Have received any prior doxorubicin or anthracycline equivalent.\n* Previous radiation to the mediastinal or pericardial area.\n* A known allergy to albumin.\n* HIV infection with CD4+ count \\\u003C 350 cells\u002FµL or Acquired Immunodeficiency (AIDS)-defining opportunistic infection in previous 12 months.\n* Pregnant (positive serum or urine pregnancy test) or lactating.\n* Previous treatment with an investigational agent or the non-approved use of a drug or device withing 4 weeks of study entry.\n* Uncontrolled diabetes mellitus.\n* Patients who require concomitant use of strong inhibitors or inducers of CYP3A4, CYP2D6 or P-glycoprotein (P-gp).",{"count":122,"type":20},67,[23,24],"This is a Phase 1b\u002FIIa dose escalation clinical trial determining the recommended phase II dose of SPEDOX-6 in subjects with advanced, therapy-refractory soft-tissue sarcoma (STS); triple-negative breast cancer (TNBC); Non-small cell lung cancer (NSCLC); cervical cancer; ovarian cancer; KRAS mutant pancreatic ductal adenocarcinoma. These are subjects who have not previously been treated with anthracyclines.",[126,127,27,128,129,44],"Soft-tissue Sarcoma","Triple Negative Breast Cancer","Cervical Cancer","Ovarian Cancer","2025-07-02",{"date":132,"type":83},"2025-07-14",{"date":134,"type":83},"2025-04-30",{"date":136,"type":20},"2031-12-31",{"name":138,"class":90},"University of California, Irvine",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":146,"enrollmentInfo":147,"targetDuration":4,"studyType":21,"phases":149,"briefSummary":150,"conditions":151,"keywords":154,"overallStatus":159,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":113},"100551134","phase-1-trametinib-plus-anlotinib-combined-with-tislelizumab-in-kras-mutant-nsclc-100551134","NCT06456138","Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC","Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant Advanced Non-small Cell Lung Cancer Patients: a Multi-center, Open-label, Phase 1\u002F2 Study","Inclusion Criteria:\n\n1. According to the 8th edition of the AJCC\u002FUICC TNM staging system for NSCLC, patients with locally advanced (stage III B\u002FIII C), metastatic or recurrent (stage IV) NSCLC confirmed by histology or cytology who are unable to undergo surgery and radical concomitant radiochemotherapy and are confirmed to have at least one measurable lesion according to RECIST 1.1.\n2. KRAS mutation positive detected by ARMS or NGS;\n3. Have been treated with 1st line of standard therapy and experienced disease progression;\n4. Patients who were assessed as CR, PR, or SD (reduction) after being treated with 2 cycles of anlotinib and trametinib.\n5. No active brain metastases;\n6. Age ≥18 years and ≤75 years;\n7. ECOG PS score: 0 to 2;\n8. Palliative radiotherapy must be completed 7 days before the first dose of study drug is administered;\n9. The main organs function is normal, that is, the following criteria met:\n10. Good hematopoietic function, defined as absolute neutrophil count ≥1.5×10\\^9 \u002FL, platelet count≥100 ×10\\^9 \u002FL, hemoglobin ≥90g\u002FL \\[no blood transfusion or no erythropoietin (EPO) dependence within 7 days before enrollment\\]\n11. Biochemical test results should meet the following criteria: BIL \\\u003C 1.25 times the upper limit of normal value (ULN); ALT and AST \\\u003C 2.5 × ULN; in case of liver metastases, ALT and AST \\\u003C 5 × ULN; Cr ≤1.5×ULN or creatinine clearance (CCr) ≥60ml\u002Fmin; Coagulation function is good, INR and PT ≤1.5 times ULN; if the subject is receiving anticoagulant treatment, PT should be within the prescribed range of use of anticoagulant drugs;\n12. Women of child-bearing age should agree to take contraceptive measures (such as intrauterine devices, contraceptives or condoms) during the study and within 6 months after the study; non-breast-feeding patients whose serum or urinary pregnancy test should be negative; male patients should agree to take contraceptive measures during the study and within 6 months after the study.\n13. Patients are voluntarily enrolled into the study, sign the informed consent form and have good compliance.\n\nExclusion Criteria:\n\n1. Small cell lung cancer (including mixed small cell and non-small cell lung cancer);\n2. Patients who have received previous treatment ≥ 4th lines of standard therapies.;\n3. There are obvious bleeding symptoms or active autoimmune disease;\n4. Patients with other driver mutation.\n5. Patients with many factors affecting oral medication, such as dysphagia, gastrointestinal resection, chronic diarrhea and intestinal obstruction;\n6. Patients who are known to have active brain metastases, spinal cord compression, carcinomatous meningitis, or brain or leptomeningeal disease diagnosed by CT or MRI at the time of screening;\n7. Patients with severe and \u002F or uncontrolled diseases, such as:\n8. Unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction within 6 months before randomization, severe uncontrolled arrhythmias; uncontrolled blood pressure (systolic blood pressure \\> 140 mmHg, diastolic blood pressure \\> 90 mmHg);\n9. Active or uncontrolled serious infection;\n10. Liver diseases such as cirrhosis, decompensated liver disease, acute or chronic active hepatitis;\n11. Not completely controlled eye inflammation or eye infection, or any condition that may lead to the above-mentioned ocular diseases\n12. Poorly controlled diabetes (fasting blood glucose (FBG) \\> 10mmol\u002FL);\n13. Routine urine test result indicates that urine protein ≥++, and 24-hour urine protein quantitation is confirmed to be \\> 1.0 g;\n14. Active tuberculosis, etc.;\n15. Uncontrolled hypercalcemia (\\> 1.5 mmol\u002FL calcium ion or calcium \\> 12 mg\u002FdL or corrected serum calcium \\> ULN), or symptomatic hypercalcemia requiring continued diphosphate therapy;\n16. Long-term unhealed wounds or fractures;\n17. Patients who have a history of psychotropic drug abuse and cannot abstain from it or have mental disorders;\n18. Patients who are known to have severe allergies (≥ grade 3) to active ingredients and any excipients of study drugs;\n19. Patients who have other malignant tumors (except radical cervical carcinoma in situ, non-melanoma skin cancer, etc.) at the same time; patients who are evaluated by the investigator to have concomitant diseases that seriously endanger the safety of the patients or affect the patients completing the study.\n20. The subjects or their sexual partners cannot or refuse to take effective contraceptive measures during the clinical trial.\n21. Pregnant or breast-feeding women.\n22. Patients who are allergic to any medicine or any ingredient; the patients with a history of treatments involving MEK inhibitors (trametinib, selumetinib, etc.) and RTKs inhibitors (anlotinib, sorafenib, apatinib, cabozantinib, etc.) were considered ineligible.\n23. Patients in other situations who are evaluated by the investigator to be ineligible to be enrolled.","75 Years",{"count":148,"type":20},60,[23,24],"Lung cancer is the most common cause of cancer-related death worldwide. Approximately 85% to 90% of lung cancer cases are non-small cell lung cancer (NSCLC), of which KRAS is one of the most common driver genes, occurring in 25-30% of lung adenocarcinomas and 3-5% of squamous cell carcinomas. KRAS-mutant NSCLC had been considered undruggable in past decades. This research sought to address a significant challenge in treating NSCLC with KRAS mutations, which are notoriously difficult to target effectively. Here, we proposal that the combined use of anlotinib and trametinib combined with tislelizumab may form an effective strategy for the treatment of KRAS-mutant NSCLC patients.",[44,152,153],"Advanced Lung Cancer","Refractory Tumor",[155,156,157,158],"KRAS-mutant NSCLC","Trametinib","Anlotinib","Tislelizumab","NOT_YET_RECRUITING","2024-06-10",{"date":162,"type":83},"2024-06-13",{"date":164,"type":20},"2024-07-01",{"date":166,"type":20},"2028-12-31",{"name":168,"class":90},"Shanghai Chest Hospital"]